| Literature DB >> 29596008 |
Jennifer L McLaren1,2,3, Erin R Barnett1,2,3,4, Milangel T Concepcion Zayas1, Jonathan Lichtenstein1,2,3, Stephanie C Acquilano3, Lisa M Schwartz3,5,6,7, Steven Woloshin3,5,6,7, Robert E Drake3.
Abstract
INTRODUCTION: At least 20% of children in the U.S. are highly vulnerable because they lack healthcare and protection. Several factors produce vulnerability: trauma, disruptions of parenting, poverty, involvement in the juvenile justice and/or child welfare systems, residence in restrictive settings, and problems related to developmental disabilities. These children receive psychotropic medications at high rates, raising numerous concerns. AREAS COVERED: The authors begin this review with a description of the population of highly vulnerable children. They then follow this with a review of the effectiveness and side effects of psychotropic medications for their most common diagnoses, using the highest-quality systematic reviews identified by multiple database searches. EXPERT OPINION: Highly vulnerable children receive numerous psychotropic medications with high rates of polypharmacy, off-label use, and long-term use, typically in the absence of adjunctive psychosocial interventions. The current evidence contravenes these trends. Future studies of psychotropic medications in vulnerable children should include long-term effectiveness trials and polypharmacy in conjunction with evidence-based, family-centered, psychosocial treatments.Entities:
Keywords: Psychotropic medication; behavior problems; child welfare; children; developmental disabilities; mental health; off-label; polypharmacy; trauma
Mesh:
Substances:
Year: 2018 PMID: 29596008 DOI: 10.1080/14656566.2018.1445720
Source DB: PubMed Journal: Expert Opin Pharmacother ISSN: 1465-6566 Impact factor: 3.889